SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 30, 2003
Noven Pharmaceuticals, Inc.
| Incorporated under the laws of the | Commission File Number | I.R.S. Employer Identification Number | ||
| State of Delaware | 0-17254 | 59-2767632 |
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 Press Release dated April 30, 2003 | ||||||||
Item 9. Regulation FD Disclosure (information furnished in this Item 9 is furnished under Item 12).
In accordance with Securities and Exchange Commission Release No. 34-47583, the following information, which is intended to be furnished under “Item 12. Results of Operations and Financial Condition,” is instead being furnished under “Item 9. Regulation FD Disclosure.” The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 12 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
On April 30, 2003, Noven Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2003. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NOVEN PHARMACEUTICALS, INC. | |
| /s/ Jeffrey F. Eisenberg Jeffrey F. Eisenberg Vice President, General Counsel and Corporate Secretary |
Date: May 6, 2003
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release dated April 30, 2003 |